Prostate cancer with biochemical relapse recurrent prostate cancer
Conditions
Interventions
None listed
Sponsors
Catharina-ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Biochemical recurrence of prostate cancer and eligible for PSMA PET for restaging and at least one visually PSMA positive tumour site and mentally competent
Exclusion criteria
Exclusion criteria: Age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantification of absolute PSMA uptake (SUVmax en SUVpeak) and intrapatient variability of PSMA uptake in tumor lesions and normal tissues, including muscles, liver, spleen, bone marrow. Primary endpoints: Absolute values and intrapatient variability of PSMA uptake in tumor lesions Absolute values and intrapatient variability of PSMA uptake in muscle Absolute values and intrapatient variability of PSMA uptake in liver Absolute values and intrapatient variability of PSMA uptake in spleen Absolute values and intrapatient variability of PSMA uptake in bone marrow Absolute values and total variability of PSMA uptake in all tumor lesions irrespective of size | — |
Secondary
| Measure | Time frame |
|---|---|
| Quantification of absolute values and intrapatient variability in PSMA uptake in tumour lesions and normal tissue, with or without Q.Clear reconstruction. Secondary endpoints: 2.2.1 Secundaire eindpunten: Absolute values and intrapatient variability of PSMA uptake in small tumor lesions = 3 cc, with or without Q.Clear Absolute values and intrapatient variability of PSMA uptake in muscle, with or without Q.Clear Absolute values and intrapatient variability of PSMA uptake in liver, with or without Q.Clear Absolute values and intrapatient variability of PSMA uptake in spleen, with or without Q.Clear Absolute values and intrapatient variability of PSMA uptake in bone marrow, with or without Q.Clear | — |
Countries
Netherlands
Outcome results
None listed